ICI targeting the Programmed Cell Death 1 and Programmed Cell Death Ligand 1 (PD-1/PD-L1) axis represents one of the most widely used and effective therapies in NSCLC [25]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.